T he American CancerS ociety estimatest hati n2 007 approximately 4,600p atientsa re goingt ob ed iagnosed with chronicm yeloid leukemia (CML)i nt he United States.CML accounts forapproximately 15%to2 0% of all adult leukemias, whichincludeschronic lymphocyticleukemia,acute myeloid leukemia (AML), anda cute lymphoblastic leukemia (ALL), andt he incidencei sa pproximately 1t o1 .5 per1 00,000 people. 1 Fortunately, only 12%t o1 5% of thesep atientsa re estimated to dief romt hisd isease becauseo ft he availability of kinase inhibitors andt he useo fa llogeneich ematopoietic stem cell transplants.Kinaseinhibitorsdonot cure thedisease;rather, they hold it in check forawhile.
■■ DiagnosisofCML
The standard CMLw ork-up will initiallyi nvolve ah istory and ap hysicale xamination. Blood is drawnt oo btainac omplete blood count( CBC) with plateletsaswellasabaselinechemistry to assesstheir renal function and hepaticfunction. Otherassessments, such as morphologicalassessments of bone marrow aspirates, cytogenetics, fluorescence in situ hybridization(FISH), and polymerasec hain reaction (PCR) will be describedbelow.CML canp resent at anyage; however, themedian agef or diagnosisis 53 years. The diseasecan be dividedinto3phases, anddiagnosis canoccur in anyofthese phases.
Clinicalf indingsa ssociated with CMLh aveb eenw ell described. 2 More than8 0% of patients complain of fatigue, regardless of thephase of CML. Interestingly, approximately 40% of thesep atientsg ot ot heir primaryc arep hysiciansf or somethingu nrelated,a nd in thep rocess it is determined thatt heir whiteb lood cell (WBC)c ount is abnormally high.O therwise, thesep atientsa re asymptomatic regardingt heir CML. These patients arei nw hati sc alledt he chronicp hase (CP) of CML. At least40% of patients presentwithsplenomegaly. Thespleen, andsometimes theliver,becomepackedwithcells.Thisleads to sensations of earlysatiety,inadditiontoweightlossand anorexi a. Bone pain is also af eature. CMLb yd efinition involves aWBC count> 25,000.E rythrocytosis, increasedp lateletc ounts, and basophiliaa re also heralding factorso fC ML,s pecificallya st he diseasemoves into themoreadvancedstages. Thebonemarrow is hypercellularwithevidenceofmyeloid hyperplasia.
■■ Clinical Phases of CML
CMLcan be dividedintothe CP,which is followed by theaccelerated phase( AP)a nd subsequently theb lastic phase( BP). AP andB Ps ometimes arel umpedt ogether andc onsideredt ob e advanced-phaseCML.The entire continuumfromCPtoBPlasts am edian of 3t o5y ears.T histimeperiodcan be broken down into theC P, which, if untreated,l asts for2t o5y ears;t he AP,
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OBjeCTIve: To review themolecular pathogenesis of CML,describethe clinicalcourseofthe disease,and explainthe currentapplication of cytogeneticsand moleculartesting fordiagnosis andtreatment.
SuMMAry: CML is caused by thetranslocation of chromosomes9and 22 to create what is called thePhiladelphia chromosome. This translocation removesacritical regulatorydomainfromthe tyrosine kinase,ABL,such that itsprotein productisconstitutivelyactive. This meansthatthe cell escapes theconstraints of normal cell growth andproliferatesuncontrollably.The modifiedprotein is knownasBCr-ABL,and it causes CML by phosphorylatingnumerousdownstream proteinsinvolvedinthe activation of cell division, amongother functions. during theearliest phaseof thedisease, thechronic phase, kinase inhibitorsthattargetBCr-ABL are effectiveinstopping disease progression. However, aminorityofpatients remain unresponsive to this therapy.
Laboratory testsare thus of greatimportance forthisdisease. not only are they required forthe diagnosis of CML,but duringtherapy they can establish thedegreeofresponse.Thatresponse, in turn,can supply theclinician with agoodestimate of theprognosis forthe patient. Thetests used for CML includecompleteblood count(CBC) with platelets, cytogenetic analysis,fluorescence in situ hybridization (FISH),and quantitativepolymerase chainreaction (PCr). These testsvaryinthe difficulty of application andin thesensitivity. CBCiscommonplacewithin theaverage hospitallaboratory, whereascytogenetic analysis, FISH,and PCr requirespecializedequipment,personnel,and training. Hematologic counts arethe least sensitive measures of disease,withalimitofdetection of aleukemic burden of 1011 cells. Cytogeneticscan detectaburdenof109 cells. Finally, quantitative PCr can detectaburdenofasfew as 105leukemic cells.The currentcosts of these testsrange fromapproximately $375 to $1,500 andmustbeperformed every3to6monthstofollowthe patient'sresponse to therapy.
COnCLuSIOn:The advent of kinase inhibitor therapyfor CML has greatlyincreasedthe importance of sensitiveanalysisofdiseaseburden. Subsequenttesting duringtherapy greatly improves theability of thecliniciantopredictthe therapeuticoutcome. Signsofearly treatmentfailure cangivethe patienttime to switchtherapies beforethe disease progresses to an advancedstage.
whichcan last up to ay ear; andfinallythe fatalB P, whichlasts from 3t o6m onths. As stated previously,ap atient canp resent in anyofthese 3stages.
TheI nternationalR andomizedI nterferonv ersusS TI571 (IRIS) trialw as ap ivotal studyt hatc reated some useful definitions. 3 CP is definedashavingwithin theperipheral blood and bone marrow less than15% blasts,lessthan20% basophils, and less than3 0% blasts plus promyelocytes,witht he Philadelphia chromosome (Ph; t9:22chromosomaltranslocation)being presentinthese transformedcells.Itisduringthisphasethatkinase inhibitors have hadsuchamarkedeffect on therapy.
TheA Ph as been definedd ifferently by different medical groups.S okal et al.o riginallyp roposedt hatA Pw as achieved whenblastsare ≥ 5% of both theperiphery andthe bone marrow; basophilsare ≥ 20%o fthe periphery; andp lateletsare >1012/L or arel ow;a nd evidence exists of clonal evolution, progressive splenomegaly, anda nemia. 4 In comparison,t he International Bone Marrow TransplantRegistry(I BMTR)defines AP as ≥ 10% blasts in thep eripherya nd bone marrow,w ith ≥ 20%o ft he peripheryb eing made up of ac ombination of basophilsp lus eosinophils; thep resenceo fap ersistentt hrombocytosis; and again, evidence of clonal evolution, progressive splenomegaly, anda nemia. Finally, the WorldH ealth Organization (WHO)d efines AP as blasts comprising1 0% to 19%i nb otht he peripherya nd bone marrow, with basophilsa ccountingf or >20% of thep eriphery,p latelet counts <1011/Lo r> 1012/L,a nd evidence of clonal evolution andp rogressive splenomegaly. 7 Commonalities betweent hese different scales area ni ncreasingn umbero fp eripheralb lasts, increasedperipheral basophils, andthe presence of clonal evolution.A dditionally, thesep atientsa re beginningt of aili nt heir response to therapy.
Clonal evolutioni sd efined as thea ppearanceo fc ytogenetic abnormalitiesinadditiontothe Ph.Approximately 50%to80% of patients whop rogressexhibit thesea bnormalities.One commonfinding is theappearanceofasecond Ph.Trisomy 8, another common cytogenetic abnormality associated with AP CML, consists of 3copiesofchromosome 8. Other abnormalities, such as isochromosome 17q,ordeletions of thep53 tumorsuppressor gene (chromosome 17p),alsoare observed.
BP is characterizedb yam uchh igherp ercentageo fb lasts, both in thep eriphery andb onem arrow. WHOd efines BP as ≥ 20%b lastsi nt he peripheryo rn ucleated bone marrow cells, extramedullary blastp roliferation,and thep resenceoflarge foci or clusters of blasts in bone marrow biopsies. 8 IBMTRdefines the BP as ≥ 30%blastsinthe peripheryorbonemarrow, alongwith extramedullary infiltrateso fl eukemic cells. 8 Perhapst he most importantaspect of BP is thatittransformsintoanacute leukemia andhas to be treated as such.Interestingly, 60%to70% of patients transform into amyeloid leukemia,whereas20% to 30%ofthese patients have thecapability of transformingintoalymphoid blast crisis thatistreated as an ALLasopposed to an AML.
■■ BiologyofCML
Examinationofthe chromosomalstructure of cellsoflymphoid, eosinophil,o rp lateletlineage from thepatient with CMLshows thatall theselineagescontain thePh. This indicatesthatCML is astemcelldisease.Todefineitmorespecifically, CMLisamyeloproliferativedisorder. It is aclonalexpansion of thetranslocation of chromosomes9and 22. The consequenceofthistranslocation is thec reationo fa nu nregulated tyrosine kinase activity.C ML wasfirst describedin1 960and wasthe firstdisease statet obe associated with aspecificcytogenetic abnormality. 9 Chromosome 9c ontainst he tyrosine kinase gene,A BL, namedf or theA belson murine leukemia virus. Chromosome 22 contains theB CR (for breakpoint clusterr egion).I nC ML a translocation occurs to form ad iffe rentc hromosome,a nd this chromosome encodesf or an oncoprotein thath as verys trong tyrosine kinase activity.Ass uggested by itsname, theB CR has multiple sitesa tw hich theb reakpointc an occur. Theseb reakpoints have differenti mplications fort he aggressiveness of the disease. 10 The p210 form of BCR-ABListhe m ost common form observed in patients with CML. The p230 form of BCR-ABL actually is associated with am orei ndolentd isease.F inally, the p190 form of BCR-ABLi sa lsod iagnosticf or theP h, butt hisi s most commonly seen in ALLasopposed to CML. The ABLgene region hasjust1breakpoint; thu s, thereare no variants thatcan affect disease. The ABLp rotein normally is ar egulated kinase with theusual constraintsofakinase. In contrast,the BCR-ABL kinase continuest op hosphorylate downstream proteint argets associated with cellular proliferationw ithout constraint.T hese targetsi nclude RAS, RAF, andA KT,a mong others.2I na ddition to dysregulatingproliferation,these phosphorylation events also create changesinthe adherence properties of thesec ells as well as diminishedapoptosis (programmedcelldeath). Allthese alterationsthenleadtothe developmentofCML.
■■ Monitoring thePatient With CML
At diagnosisi ti se stimated thatap atient hasal oado f1 012 leukemic cells ( Figure) . Assumingt hatt he patientr espondst o therapy, thefirst assessmentistodeterminethe number of blasts andb asophils in ab lood sample. If therea re no or fewb last cellsinthe blood andthe blood countreturns to within normal limits,thisisreferredtoasahematologicresponse(HR).8Ifthe assessmenti st hatn ol eukemic cellsc an be detected,t he HR is complete (CHR); otherwise it is partial( PHR).Ass hown in the Figure, t hisC HR assessmenth as al imit of detectinga pproximately 1011 leukemic cellso rm orei nt he body. An additional aspect of theCHR is thelossofany sign of splenomegaly.
The next levelo fa ssessment is cytogenetics. Usingc hromosomalspreads or FISH,the number of cellscontainingthe Ph is determined.T he reductioni nl eukemic cellso bserved by these Allthese assessmentsa re measureso fr esidual disease.T hey areimportant,asithas clearlybeen d emonstrated thatthe lower theleukemiccellburden, thelongerthe therapeuticresponseand thebetterthe outcomefor thepatient.
Cytogenetics( karyotyping) is performedo nab onem arrow biopsy.The cellsderivedfromthe biopsy areculturedf or 1to3 days,allowingsomeofthemtoenter themetaphasestate of mitosis, wherethe chromosomesare condensed andwhere cytogeneticsc an be assessed.A tt hisp oint thec ells ares tained andt he chromosomesa re then identified on theb asis of characteristic bandsoflight anddarkstaining. The sizesand patterns of these bandsallow thei dentificationn ot only of normal chromosomes butalsoo ft ranslocations, amplifications,and deletions.T he Ph is thus identified by itsuniquepattern of bands.
Thec ost of this test at EmoryH ealthcare is approximately $1,500.I ti sac rucial test andi sa lwaysd onea td iagnosis.N ot only does it enablethe identification of theP hb ut it also shows thepresenceofother cytogenetic abnormalities.Thistestwill be essential in determiningw hether clonal evolutionh as occurred within theb onem arrows tem cell poola nd thus whether the patienth as progressed beyond theC P. Furthermore,i ti sa n essential test to be performedifdisease progressionissuspected. The5 -years urvivald ataf romt he IRIS trials howt hatp atients with CMLw ho have no CR at 24 months have an 82%c hance of survival at 5y ears. 11 In comparison,p atientsw ithC ML who achieveaC CR at 24 months have a 99%chanceo fsurvivala t5 years. If thepatient hasnot beguntorespond to therapywithin 12 months andpossiblyasearly as 3months, guidelines recommend thattherapy be switchedatthispoint rather thanatalater date.
FISH involves theu se of fluorescent probes to visuallyd emonstrate thepresenceofthe t(9:22)translocation.The probethat bindst oas pecifics equencew ithin theA BL gene is attached to ar ed fluorescentm arker. The probet hatb inds to theD NA sequence within theBCR is then attached to agreen fluorescent marker.Ifthe translocationhas occurred,the 2probeswill be so closetogether thattheir colors fuse to produceyellow. FISH hasa superior sensitivitytocytogenetics. In theformer case,onlycells in metaphasecan be assessed, andaminimumo f2 0cells must be done.T hus, thel imit in sensitivityc an be as lowa s1i n2 0 cells. In comparison,FISHisnot performedonmetaphase cells, andseveral hundredcan be scannedwithin asampleassessment. FISH also canb ep erformed on blood or bone marrow tissue. The cost forFISHisapproximately $1,000.
Quantitative PCRisb yfar them ostsensitive assay available. The RNAs amplei sp reparedf romt h eb lood or bone marrow samplea nd reverset ranscribed to make complementaryD NA (cDNA).T he cDNA is then amplifiedf or BCR-ABLt ranscripts andtranscripts fora" housekeeping"g ene, such as G6PD,using primersthatare specific forthe 2g enes.Because theamounto f material doublesineachcycle,itispossible, once thesampleha s reacheds omep redetermined levelo fa mplification,t oq uantify thea mounto fs tartingm aterialb yc ountingc ycles. To account forp otentiald ifferencesi ns tartingc elln umbers,t he starting material is normalized to theamountofhousekeepinggenestartingmaterial. At present, PCRcan detect even 1Ph+ cell within a sampleof1million cells.
The cost of thet esta tE mory Healthcare runs about$ 370; however, thet estr equiress pecializede quipment andt raining. Oftent he test is sent outt ob ep erformed,w hich mayi ncrease thecostand thetimebut decreasesthe burden on thetechnical staff. There hasb een some controversy over usingt hist esta t diagnosis; however, thereasons fordoing so arebecomingmore apparent. Most important, theperformance of this test at diagnosisgives theclinician afirmbaselinemeasure of diseaseagainst whichtherapeuticresponsecan be measured.
Again, returningt ot he 5-year survival data from theI RIS trial, patients on imatinibt herapyw ho achieved aC CR and greaterthanorequal to a3-log reductioninBCR-ABL transcripts hada100%survivalat5years.Patientsonimatinibtherapy who didnot achieveaCCR hadan88% survival rate at 5years.
The criteria fort he variousr esponses just describeda re as follows: PHRa nd CHRa re differentiated by thep resenceo f immature blasts andsplenomegaly. The CR is generallydescribed in termso fp ercentages of Ph+m etaphases, with them inor CR rangingfrom35% to 90%and themajor CR rangingfrom1 %to 34%. ACCR is theabsence of detectable Ph+metaphases. Finally, amajor molecularresponseisdefined as at leasta3-log reduction in BCR-ABLt ranscripts,a nd ac ompletem olecular response is defined as thecompleteabsence of detectable transcripts. TheT ables hows al isto fr ecommended testsd uringt he course of diagnosisand treatmentand during thevariousstages of thedisease, derivedfromthe workofT efferi et al. 12 In general, thet ests beginw itht he leasts pecific, most readilya vailable. Cytogeneticso rF ISHt ests arep erformed every3t o6m onths untilaCCR is achieved.Atthatpoint,the examinationswitches to PCR, whichi sr epeated every3t o6m onthst hroughoutt he patient'st imeo ft herapy.T he onep oint of controversyi nt his Tableisthe useo fPCR during diagnosis. Forthe reasonsstated above, this author believes strongly thatthe PCRt ests houldb e included at diagnosis.
■■ Conclusions
CMLtherapy has improved to thepoint where only asmall percentageo fp atientsa re expected to dieo fthe disease. However, survivorsa re notc ured. Rather,t heir diseasei sh eldi nc heck. This hasp lacede venm orei mportan ce on laboratory testsa s meanso fd iagnosis anda na ssessmento ft herapeuticr esponse. Standard assayssuchasCBC andcytogenetics, although less sensitive,are importanttools becauseoftheir ubiquity andprognosticpower.Morespecializedtests,suchasFISHand PCR, require more training; however, theirs ensitivity allowst he clinician to quantify residual disease. PCRi se merginga sat estt op erform from diagnosisthroughouttherapybecause of itsimmense power to establishabaselineatdiagnosis andtoestablish thedegree of response even at earlyt imep ointsi nt herapy. Thesee arly data will be essentialt ohelpi dentifyn onrespondersand allow them to switchtherapiesatanearly stageofdisease progression.
